News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Advanced Plant Pharmaceuticals, Inc. (APPI) Acquires 99 Percent Of Mazal Plant Pharmaceuticals Inc., A Company Focused On Developing Three Drugs For FDA Approval Process



10/19/2005 5:12:20 PM

David Lieberman, CEO of Advanced Plant Pharmaceuticals, Inc., (OTCBB:APPI) confirmed today the closing of an asset sale agreement entered with Mazal Plant Pharmaceuticals Inc., a private Delaware corporation ("Mazal") whereby in exchange for of 7,000,000 shares of common stock of Mazal, APPI transferred intellectual property to Mazal relating to three whole plant pharmaceutical drugs. Mazal presently has 7,050,100 shares of common stock issued and outstanding. Mazal is focused on the FDA development, testing, manufacturing and selling of plant pharmaceutical drugs.

Read at Prime Zone


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES